| Entry |
|
|---|
| Name |
Tadocizumab (USAN) |
|---|
| Formula |
C2107H3252N562O673S12
|
|---|
| Exact mass |
47579.4170
|
|---|
| Mol weight |
47608.53
|
|---|
| Sequence |
(A chain)
QVQLVQSGAE VKKPGSSVKV SCKASGYAFT NYLIEWVRQA PGQGLEWIGV IYPGSGGTNY
NEKFKGRVTL TVDESTNTAY MELSSLRSED TAVYFCARRD GNYGWFAYWG QGTLVTVSSA
STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCDKTH
(B chain)
DIQMTQTPST LSASVGDRVT ISCRASQDIN NYLNWYQQKP GKAPKLLIYY TSTLHSGVPS
RFSGSGSGTD YTLTISSLQP DDFATYFCQQ GNTLPWTFGQ GTKVEVKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: A22-A96, A146-A202, A222-B214, B23-B88, B134-B194) |
|---|
| Type |
Peptide |
|---|
| Efficacy |
Platelet aggregation inhibitor, Anti-glycoprotein IIb/IIIa antibody |
|---|
| Type |
Monoclonal antibody, bispecific antibody |
|---|
| Comment |
Treatment of patients undergoing percutaneous coronary interventions
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Brite |
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Cell adhesion molecules: other families
Integrins
ITGA2B/ITGB3
D06649 Tadocizumab (USAN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
